Delivery Order SPE2DB20D3103-SPE2DB23FL3Y1
- Not listed
- This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Humira (adalimumab) medication, a specialty pharmaceutical product used to treat various medical conditions. The contract, valued at $3,523.38, is a firm fixed-price delivery order with a completion date of November 30, 2023. Amerisourcebergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the...
- This contract award from the Defense Logistics Agency (DLA) Troop Support Medical for $25,284.40 to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Humira (Adalimumab) medication. The contract is a firm-fixed price delivery order with an ultimate completion date of October 12, 2023. This award is not designated as a set-aside contract. Amerisourcebergen, as a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- The federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $2,499.61 delivery order is for the pharmaceutical product Humira (CF) 40 mg/0.4 ml syringes. The contract has an ultimate completion date of October 30, 2023 and is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of Humira (adalimumab) medication. The contract has a ceiling value of $7,538.88 and runs through October 17, 2023. This is a delivery order contract with a firm fixed price pricing type. The contract does not have a set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen Drug Corp holds a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Humira (adalimumab) medication. The delivery order, valued at $4,498.16, is part of a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and AmerisourceBergen, worth up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for AmerisourceBergen to provide a comprehensive...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the supply of Humira (adalimumab) medication with a ceiling value of $18,855.20 and a completion date of March 13, 2024. The award is not designated as a set-aside and was made through full and open competition. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This is a delivery order from the Defense Logistics Agency (DLA) Troop Support Medical awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of the specialty medication Humira (adalimumab) at a firm fixed price of $3,002.48. The contract has an ultimate completion date of January 3, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This federal contract award is for the delivery of Humira (adalimumab) 40 mg/0.4 mL syringes to the Defense Logistics Agency (DLA). The $2,110.49 Firm Fixed Price Delivery Order was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distributor. The contract has a completion date of February 29, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Humira (adalimumab) medication. The contract has a ceiling value of $1,174.44 and a period of performance through July 12, 2022. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a...
- This contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00. The contract provides for the delivery of Humira (adalimumab) pharmaceutical products to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract has a firm fixed price structure and is not designated...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB23FL3Y1Delivery Order
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the supply of the pharmaceutical product Humira (adalimumab). The $12,902.88 firm fixed-price contract has an ultimate completion date of October 21, 2022. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a wide range of pharmaceutical and medical supplies to support military healthcare programs globally. This delivery order is part of that larger IDC and does not have a set-aside designation, indicating open competition. Amerisourcebergen also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.9k | 10/20/22 |